Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
References:
[1]. Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021;11(12):2998-3007.
[2]. Sabree SA, Voigt AP, Blackwell SE, et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J Immunother Cancer. 2021;9(6):e002484.
[3]. Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J Immunother Cancer. 2020;8(2):e000940.
[4]. Negrao MV, Papadimitrakopoulou VA, Price AC, et al. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in PatientsWith Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.JTO Clin Res Rep. 2022;4(3):100423. Published 2022 Oct 26.